Vaxart, Inc.

VXRT OTC CIK: 0000072444

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
Phone (650) 550-3500
Fiscal Year End 1231
EIN 591212264

Financial Overview

FY2025 FY

$237.26M
Revenue
$107.46M
Total Liabilities
$87.80M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 31, 2026 View on SEC
4 Insider stock transaction report March 31, 2026 View on SEC
4 Insider stock transaction report March 26, 2026 View on SEC
4 Insider stock transaction report March 26, 2026 View on SEC
4 Insider stock transaction report March 26, 2026 View on SEC
4 Insider stock transaction report March 26, 2026 View on SEC
4 Insider stock transaction report March 20, 2026 View on SEC
4 Insider stock transaction report March 20, 2026 View on SEC
4 Insider stock transaction report March 20, 2026 View on SEC
4 Insider stock transaction report March 20, 2026 View on SEC

Annual Reports

10-K March 13, 2026
  • Developing oral recombinant vaccines using proprietary VAAST™ platform, offering easier administration, storage, and distribution.
  • Secured ATIRRPV government contract, projecting $5 million revenue in 2025, providing stable funding.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.